Summary of "This Supplement Has 0.2% Absorption — and It Still Works"

Concise summary

The video reviews evidence for oral hyaluronic acid (HA) supplements for skin — what works, how (or whether) it’s absorbed, and practical takeaways. Overall: oral HA can deliver modest, measurable skin benefits and has an excellent safety profile, but effects are modest, mechanisms are likely indirect, and high‑molecular‑weight HA offers no clear advantage over low‑molecular‑weight forms.

Key human trial findings

Recent randomized, double‑blind human trial (Scientific Reports, Dec 2025; n = 150; 12 weeks) tested oral sodium hyaluronate:
- Primary outcome: cheek hydration increased by 11.5% vs placebo at the higher dose (120 mg/day). The lower dose produced ≈9.1% increase.
- Other improvements: reduced transepidermal water loss (TEWL), reduced oil production, reduced eye‑wrinkle depth, increased skin thickness and density, and more moisturizing molecules in the upper epidermis.
- No change observed in skin color, pore size, or skin gloss.
Earlier human trials report mixed but generally positive results:
- Small 2007 study: reduced periorbital wrinkles after 8 weeks.
- 2021 trial: ~18.8% wrinkle reduction in HA group vs ~2.6% in placebo.
- 2023 study (n = 129): multiple skin benefits reported.
- Several smaller Japanese studies: improved skin moisture.
For stronger, more immediate facial volume/wrinkle effects, clinically administered injectable HA (dermal fillers) reliably improves appearance (meta‑analysis of 13 studies), but this is a different intervention with different risks and costs.

Bioavailability and likely mechanisms

Bioavailability concerns:
- A 2023 radioactive‑labeling study showed high‑molecular‑weight HA is broken down during digestion and is not absorbed intact; overall direct absorption to skin is very low (~2%).
- A 2009 animal study initially suggested some intact absorption with radioactive high‑mw HA, but later evidence favors breakdown during digestion.
Mechanisms are likely indirect rather than simple deposition of intact HA into skin. Proposed pathways include:
1. HA fragments alter the gut microbiome, promoting short‑chain‑fatty‑acid (SCFA) producers that have anti‑inflammatory and skin‑barrier benefits.
2. HA or its fragments bind gut receptors, triggering systemic anti‑inflammatory signaling.
3. HA supplementation may upregulate endogenous collagen and HA production in skin (supported by animal data).

Practical conclusions and recommendations

Oral HA can produce modest, measurable improvements in skin hydration, TEWL, oil production, wrinkle depth, and skin thickness/density. Benefits are generally modest and are best viewed as one tool among many for skin health.

If using oral HA supplements:
- Prefer low‑molecular‑weight sodium hyaluronate — high‑mw forms are broken down during digestion and add cost without clear extra benefit.
- Dosing from the 2025 trial: 120 mg/day produced the larger hydration effect; a lower dose also showed benefit.
- Expect modest improvements rather than dramatic changes.
- Safety profile is good, but long‑term effects and optimal dosing need further study.
Use supplements as part of a broader skin‑care approach: sun protection, topical care, nutrition, and lifestyle measures.

Key wellness / self‑care takeaways

Consider low‑molecular‑weight sodium hyaluronate if choosing oral HA.
120 mg/day was the higher dose in the recent positive trial; lower doses also showed benefit.
Benefits are modest: hydration, reduced water loss/oil, reduced wrinkle depth, increased thickness/density.
Mechanisms may be indirect (gut microbiome or signaling), not direct deposition of intact HA into skin.
HA supplements show good safety; further research needed on long‑term use and optimal regimens.
For immediate/stronger augmentation of volume or wrinkles, clinician‑administered HA injections (dermal fillers) are an alternative with different risks and costs.

Limitations and caveats

Many earlier trials were small, focused on specific populations (often Asian cohorts), or published in Japanese only — limiting generalizability.
Some trials lacked full statistical detail; reported effect sizes are modest.
The newer positive trial was industry‑funded and included authors employed by a supplement manufacturer — potential conflict of interest to note.
Mechanisms remain uncertain and likely multifactorial.

Sources, studies, and disclosures referenced

2023 radioactive‑labeling study: showed HA is broken down during digestion and not absorbed intact (mouse/germ‑free vs conventional gut bacteria experiments; ~2% bioavailability).
Human randomized clinical trial: Scientific Reports, December 2025 (double‑blind, n = 150, 12 weeks; sodium hyaluronate 120 mg/day vs lower dose vs placebo).
Earlier human trials (2007, 2021, 2023) and several smaller Japanese studies reporting skin benefits.
2009 animal study (rats and dogs) using radioactive high‑mw HA that initially suggested intact absorption.
Meta‑analysis of 13 studies on injected (dermal) hyaluronic acid showing facial‑skin improvements.
Product mention: microvitamin and microvitamin plus powder (contains low‑molecular‑weight sodium hyaluronate); the video’s author/team disclose use and inclusion of HA in their product.
The video narrator/researcher(s) and some study authors disclosed industry funding or employment by a supplement company.